Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
Nikolaos KotsopoulosMark P ConnollyJinjing LiPublished in: Journal of medical economics (2021)
Applying a cross-sectorial government perspective budget impact assessment improves our understanding of fiscal changes attributed to ASCVD based on changes in premature mortality and work activity and how this influences lifetime tax contributions and public benefits. The main cost driver observed was associated with reduced ASCVD events that enabled people to remain productive and paying taxes.